CDT

CDT Equity Inc. (CDT) | Rumor.io

CDT Equity

CDT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,128

Bullish sentiment (50-day avg)79%

Price to earnings ratio421.3

Market capitalization1M

Earnings per share-2.8K

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-39.2M

Social

What share of all stock conversation is about CDT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% -0.01

Sep 29

Conduit Pharmaceuticals Inc. (CDT) is undergoing a 1-for-25 reverse stock split, taking effect on September 29, 2026, with an estimated new float of ~438,000 shares.
The stock's price is expected to be around $1 tomorrow, and some investors believe it could reach $50.
The reverse split has been compared to a similar event in WHLR, where the stock price rose after the split, and some investors are betting on a similar outcome for CDT.

Generated by AI

Sentiment

Of the messages about CDT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -30	60.42% -26.58	76.7% -12.82	80.3% -0.92
Bearish	50% +30	39.58% +26.58	23.3% +12.82	19.7% +0.92

Bullish· Sep 11

$CDT has the potential for a strong bounce to the upside after a heavily dropped price, based on historical market trends.
The stock has shown a 600% increase in a short period of time, indicating a high likelihood of future price growth.
Many investors are anticipating a significant price spike, with some even loading up on the stock in anticipation of a big bounce.

Bearish· Sep 25

Conduit Pharmaceuticals Inc.'s stock ($CDT) is expected to decline further, potentially dropping below $0.05.
The company's dilutive actions, such as diluting shares to pay salaries, may be seen as a sign of financial struggles, leading to a decrease in stock value.
Conduit Pharmaceuticals Inc.'s past agreements with shareholders, which allowed for future reverse stock splits, may be viewed as unusual or even a scam, potentially eroding investor trust and affecting stock performance.

Generated by AI

Topics

Of the messages about CDT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	60%	55.56%	69.28%
Technical Analysis	0%	40%	25.93%	29.1%
Earnings	0%	0%	18.52%	1.27%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	0.35%
Macro	0%	0%	0%	0%

Announcements· Jun 4

Conduit Pharmaceuticals (CDT) has entered into a joint development agreement with Manoira to advance AZD1656 and AZD5658 in animal health.
The collaboration aims to leverage cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and capture commercial potential in the $15 billion animal health market.
The evaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 development, while preserving full ownership of intellectual property and data.

Technical Analysis· Apr 11

$CDT is expected to reverse and potentially rise after a two-day pullback, with some analysts anticipating a breakout above $1.21.
The stock's RSI is at 30, indicating it is heavily oversold and may be due for a reversal, with some traders holding strong and anticipating a rebound.
Key levels to watch for $CDT include $1.30, $1.33, $1.55, and $1.64, with some analysts suggesting a potential run-up if the stock can close above $1.30.

Generated by AI

Community

Of the messages about CDT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	64.52%	39.26%	37.56%	55.21%
Newcomers	35.48%	60.74%	62.44%	44.79%

Regulars· Sep 29

The regulars are focused on the 1-for-25 reverse stock split taking effect today, which may significantly reduce the float of CDT Equity Inc. shares.
There is skepticism among the regulars about the company's news releases and strategies, with some considering it a sign of desperation.
The regulars are also discussing the potential implications of Sarborg Limited's latest capital raise and the valuation of approximately $709 million, with CDT holding a significant stake in the company.

Newcomers· Sep 29

The newcomer investors are concerned about the company's dilution of shares, which they believe is causing the stock price to drop, and are speculating about the company's intentions and the potential impact on the stock price.
Some investors are comparing Conduit Pharmaceuticals Inc. to another company, WHLR, which experienced a significant price increase after a similar split, and are wondering if CDT could follow a similar pattern.
The newcomers are also discussing the company's recent activity, including a filing for an ATM (allotment of shares) and potential issues with brokers being unable to buy the stock, which is causing the price to drop.

Generated by AI

News

CDT Equity Announces Reverse Stock Split on Nasdaq

Detailed price information for Cdt Equity Inc (CDT-Q) from The Globe and Mail including charting and trades.

2mo agotheglobeandmail.com

Also Discussed

Investors talking about CDT also mention

#	Name	Attention
1	Presidio Property Trust, Inc. Class A Common StockSQFT	0%new
2	MURF - Murphy Canyon Acquisition Corp.	——
3	Interactive Strength Inc.TRNR	0%0
4	Aclarion, Inc.ACON	0%0
5	CERO - CERo Therapeutics Holdings, Inc.	——
6	Azitra Inc.AZTR	0%0
7	Agape Atp CorpATPC	0%0
8	NMHI - Nature's Miracle Holding Inc.	——
9	LUXH - LuxUrban Hotels Inc.	——
10	Ucommune International Ltd.UK	0%0

CDT Equity Inc.

Healthcare
Biotechnology

CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and advancing therapeutic assets through scientific innovation and strategic partnerships. CDT Equity Inc. develops clinical-stage programs across autoimmune diseases, oncology, dermatology, idiopathic male infertility, rare diseases, and animal health. Its current portfolio includes compounds such as AZD1656, AZD5658, and AZD5904, supported by an approach that combines artificial intelligence, solid-form chemistry, and asset repositioning to improve development efficiency. The company emphasizes value creation through intellectual property, out-licensing, and partnerships rather than large-scale internal drug development. CDT Equity Inc. serves as a specialized participant in the healthcare sector, aiming to bring differentiated treatment candidates into clinical and commercial pathways.

Website

Location

4581 Tamiami Trail North

Naples, FL, 34103

United States

Social

What share of all stock conversation is about CDT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% +0	0% 0	0% +0	0% -0.01

Sep 29

Conduit Pharmaceuticals Inc. (CDT) is undergoing a 1-for-25 reverse stock split, taking effect on September 29, 2026, with an estimated new float of ~438,000 shares.
The stock's price is expected to be around $1 tomorrow, and some investors believe it could reach $50.
The reverse split has been compared to a similar event in WHLR, where the stock price rose after the split, and some investors are betting on a similar outcome for CDT.

Generated by AI

Sentiment

Of the messages about CDT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	50% -30	60.42% -26.58	76.7% -12.82	80.3% -0.92
Bearish	50% +30	39.58% +26.58	23.3% +12.82	19.7% +0.92

Bullish· Sep 11

$CDT has the potential for a strong bounce to the upside after a heavily dropped price, based on historical market trends.
The stock has shown a 600% increase in a short period of time, indicating a high likelihood of future price growth.
Many investors are anticipating a significant price spike, with some even loading up on the stock in anticipation of a big bounce.

Bearish· Sep 25

Conduit Pharmaceuticals Inc.'s stock ($CDT) is expected to decline further, potentially dropping below $0.05.
The company's dilutive actions, such as diluting shares to pay salaries, may be seen as a sign of financial struggles, leading to a decrease in stock value.
Conduit Pharmaceuticals Inc.'s past agreements with shareholders, which allowed for future reverse stock splits, may be viewed as unusual or even a scam, potentially eroding investor trust and affecting stock performance.

Generated by AI

Topics

Of the messages about CDT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	60%	55.56%	69.28%
Technical Analysis	0%	40%	25.93%	29.1%
Earnings	0%	0%	18.52%	1.27%
Analysts	0%	0%	0%	0%
Controversies	0%	0%	0%	0.35%
Macro	0%	0%	0%	0%

Announcements· Jun 4

Conduit Pharmaceuticals (CDT) has entered into a joint development agreement with Manoira to advance AZD1656 and AZD5658 in animal health.
The collaboration aims to leverage cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and capture commercial potential in the $15 billion animal health market.
The evaluation of AZD5658 expands Conduit's glucokinase activator platform into novel veterinary applications, complementing AZD1656 development, while preserving full ownership of intellectual property and data.

Technical Analysis· Apr 11

$CDT is expected to reverse and potentially rise after a two-day pullback, with some analysts anticipating a breakout above $1.21.
The stock's RSI is at 30, indicating it is heavily oversold and may be due for a reversal, with some traders holding strong and anticipating a rebound.
Key levels to watch for $CDT include $1.30, $1.33, $1.55, and $1.64, with some analysts suggesting a potential run-up if the stock can close above $1.30.

Generated by AI

Community

Of the messages about CDT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	64.52%	39.26%	37.56%	55.21%
Newcomers	35.48%	60.74%	62.44%	44.79%

Regulars· Sep 29

The regulars are focused on the 1-for-25 reverse stock split taking effect today, which may significantly reduce the float of CDT Equity Inc. shares.
There is skepticism among the regulars about the company's news releases and strategies, with some considering it a sign of desperation.
The regulars are also discussing the potential implications of Sarborg Limited's latest capital raise and the valuation of approximately $709 million, with CDT holding a significant stake in the company.

Newcomers· Sep 29

The newcomer investors are concerned about the company's dilution of shares, which they believe is causing the stock price to drop, and are speculating about the company's intentions and the potential impact on the stock price.
Some investors are comparing Conduit Pharmaceuticals Inc. to another company, WHLR, which experienced a significant price increase after a similar split, and are wondering if CDT could follow a similar pattern.
The newcomers are also discussing the company's recent activity, including a filing for an ATM (allotment of shares) and potential issues with brokers being unable to buy the stock, which is causing the price to drop.

Generated by AI

CDT Equity

Social

Sep 29

Bullish· Sep 11

Bearish· Sep 25

Announcements· Jun 4

Technical Analysis· Apr 11

Regulars· Sep 29

Newcomers· Sep 29

CDT Equity Announces Reverse Stock Split on Nasdaq

Also Discussed

CDT Equity Inc.

Company Information

Location

CDT Equity Announces Reverse Stock Split on Nasdaq

Also Discussed

Social

Sep 29

Bullish· Sep 11

Bearish· Sep 25

Announcements· Jun 4

Technical Analysis· Apr 11

Regulars· Sep 29

Newcomers· Sep 29